The First Human Case of Marburg Virus in West Africa Highlights Importance of Quickly Detecting Spillover Events
The first case of fatal Marburg virus disease was identified in Guinea, West Africa on 9 August 2021. Marburg is ...
Tag: Marburg
One Drug to Defeat All Filoviruses?
While vaccines for Ebola virus are being deployed and show high efficacy, pan-filoviral treatment is still lacking. Researchers have identified ...
Marburg Infection Protective Antibody Response Mechanism Uncovered
A detailed study of the monoclonal antibodies from a person who survived a Marburg infection led researchers to identify novel ...
Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform
Soligenix, Inc. announced that its ongoing collaboration with the University of Hawai’i at Manoa (UHM) and Hawaii Biotech Inc. (HBI) ...
Bats’ Fierce Immune Systems Drive Viruses To Higher Virulence, Making Them Deadlier in Humans
A new University of California, Berkeley, study finds that bats' fierce immune response to viruses could drive viruses to replicate ...
U.S. Supporting Ecological Surveillance for Special Pathogens in Sierra Leone
The U.S. Centers for Disease Control and Prevention has issued a funding opportunity in support of improved vector surveillance and ...
Fundamental Research to Counter Biological, Chemical, and Nuclear Weapons
The Defense Threat Reduction Agency (DTRA) seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate ...
WHO Updates Blueprint List of Priority Diseases
The 2018 review of the World Health Organization’s Blueprint list of priority diseases occurred February 6-7, 2018. Given their potential ...
Inhibiting PP2A-B56 to Suppress Ebola Virus Transcription and Infection
Researchers from the University of Copenhagen and Phillips Universität Marburg have found a new target for inhibiting Ebola virus from ...
BARDA BAA 2018: Pandemic Influenza, Infectious Diseases, CBRN Countermeasures
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the advanced research and development of medical countermeasures ...
NIAID Backs VesiculoVax Vaccine for Ebola, Marburg, and Lassa Viruses
Profectus BioSciences, Inc. has received a contract for up to $22.25 million from the National Institute of Allergy and Infectious ...
Monoclonal Antibody Cures Late-Stage Marburg Infection in Monkeys
A study led by scientists at the University of Texas Medical Branch Galveston National Laboratory and Mapp Biopharmaceutical has found ...
PHEMCE Review: Accomplishments and Future Areas of Opportunity
The United States continues to face national security risks from natural, accidental , and intentional health threats. Efforts to improve ...
GAO Recommendations on Select Agent Program Improvements
The total number of incidents involving incomplete inactivation—a process to destroy the hazardous effects of pathogens while retaining characteristics for ...
Advanced Development of Filovirus and Lassa Fever Vaccines
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals for advanced development of multivalent vaccines against Ebola ...
A Lengthy Arms Race Between Ebola and Bats
Ebola virus and bats have been waging a molecular battle for survival that may have started at least 25 million ...
USAMRIID Seeks Mouse Supply for Filovirus Research
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defense's lead laboratory for medical biological defense ...
DoD CBRN Medical Countermeasure Consortium
Military program managers briefed biopharmaceutical industry and research organization representatives during a Nov. 2 Industry Day, part of an initiative ...
Handicapping Ebola to Buy Immune System Time to Respond
The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as ...
RFI – Vaccine Candidates and Technologies for Filoviruses
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information from pharmaceutical and biopharmaceutical product developers on multivalent ...
